Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +0.96%76 Piotroski F-Score is 9 as of Sep. 18, 2026, which is 50% above its 10-year median of 6.00. GuruFocus rates SHSE:603387 with a GF Score™ of 76/100 and a GF Value™ of ¥7.95 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Getein Biotech ranks better than 99.88% on this metric.
Good Sign:
Piotroski F-Score is 9, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Getein Biotech has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Getein Biotech's Piotroski F-Score or its related term are showing as below:
SHSE:603387'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 9
During the past 12 years, the highest Piotroski F-Score of Getein Biotech was 9. The lowest was 3. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Getein Biotech Piotroski F-Score Related Terms
Getein Biotech Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Getein Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 52.02706722 + 78.12867683 + 76.8494105 + 108.42972685 = ¥315 Mil. Cash Flow from Operations was 100.89859318 + 154.7907787 + 86.37322001 + 130.48951403 = ¥473 Mil. Revenue was 244.99684005 + 294.02514161 + 267.50124908 + 287.83477156 = ¥1,094 Mil. Gross Profit was 150.446922465 + 195.517749165 + 172.971681285 + 180.309925935 = ¥699 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(3910.12502414 + 3836.513312 + 3755.9323742 + 3698.84313577 + 3769.89888777) / 5 = ¥3794.26254678 Mil. Total Assets at the begining of this year (Jun25) was ¥3,910 Mil. Long-Term Debt & Capital Lease Obligation was ¥0 Mil. Total Current Assets was ¥2,561 Mil. Total Current Liabilities was ¥681 Mil.
Net Income was 28.84395045 + 49.64618322 + 65.14102293 + 45.63465459 = ¥189 Mil.
Revenue was 259.34731487 + 280.95825107 + 241.38141742 + 264.89511391 = ¥1,047 Mil. Gross Profit was 164.92701772 + 176.13767881 + 168.941185495 + 146.932471815 = ¥657 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(3819.41881059 + 3839.31039865 + 3707.37458749 + 3722.9685426 + 3910.12502414) / 5 = ¥3799.83947269 Mil. Total Assets at the begining of last year (Jun24) was ¥3,819 Mil. Long-Term Debt & Capital Lease Obligation was ¥0 Mil. Total Current Assets was ¥2,321 Mil. Total Current Liabilities was ¥1,064 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Getein Biotech's current Net Income (TTM) was 315.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Getein Biotech's return on assets of this year was 0.0806713. Getein Biotech's return on assets of last year was 0.04955356.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Getein Biotech's current ratio of this year was 3.76016878. Getein Biotech's current ratio of last year was 2.1823028.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Getein Biotech's number of shares in issue this year was 507.154. Getein Biotech's number of shares in issue last year was 507.154.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Getein Biotech's gross margin of this year was 0.6389557. Getein Biotech's gross margin of last year was 0.62769883.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Getein Biotech's asset turnover of this year was 0.27987801. Getein Biotech's asset turnover of last year was 0.27401606.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Getein Biotech has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
Getein Biotech (SHSE:603387) has a Piotroski F-Score of 9 as of Sep. 18, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Getein Biotech and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, Getein Biotech's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Getein Biotech ranks #1 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Getein Biotech's Piotroski F-Score too high?
Getein Biotech's current Piotroski F-Score of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Getein Biotech's value of 9 is 80% above this industry median. Based on the distribution chart, Getein Biotech ranks #1 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #1 out of 816 companies for Piotroski F-Score. This places Getein Biotech in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Getein Biotech's value of 9 is 80% above this benchmark. Historically, Getein Biotech's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Piotroski F-Score is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.95, compared to a current price of ¥9.42 — trading 18.5% above its estimated fair value. The current Piotroski F-Score is 9, which is 50% above median its 10-year median of 6.00 and 80% above the Medical Devices & Instruments industry median of 5.00. Getein Biotech's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Piotroski F-Score is 9 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥9.42 is trading 18.5% above its estimated GF Value™ of ¥7.95.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Piotroski F-Score: 9 (50% above median its 10-year median of 6.00)
GF Value™: ¥7.95 vs. price of ¥9.42 (18.5% above fair value)
Industry Position: 80% above the Medical Devices & Instruments median (#1 of 816)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
76GF Score
Get the complete analysis for SHSE:603387
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
